CervoMed Inc.

Healthcare · Biotechnology · United States

Last price 1.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 26.46M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant...